Alpha 2.0
Login Register
» Authors » A J Plodkowski

A J Plodkowski

Explore the profile of A J Plodkowski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 932
Followers 0
Related Specialties
Oncology
Radiology
Top 10 Co-Authors
M D Hellmann
H Rizvi
G J Riely
D F Halpenny
K C Arbour
J V Egger
C M Rudin
M G Kris
M M Awad
M S Ginsberg
Published In
Ann Oncol
Lung Cancer
Clin Radiol
Affiliations
Soon will be listed here.
Recent Articles
1.
Deciphering radiological stable disease to immune checkpoint inhibitors
Luo J, Wu S, Rizvi H, Zhang Q, Egger J, Osorio J, et al.
Ann Oncol . 2022 May; 33(8):824-835. PMID: 35533926
Background: 'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset...
2.
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Schoenfeld A, Rizvi H, Bandlamudi C, Sauter J, Travis W, Rekhtman N, et al.
Ann Oncol . 2020 Mar; 31(5):599-608. PMID: 32178965
Background: Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular...
3.
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, et al.
Ann Oncol . 2019 May; 30(8):1311-1320. PMID: 31086949
Background: Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding...
4.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
Sabari J, Leonardi G, Shu C, Umeton R, Montecalvo J, Ni A, et al.
Ann Oncol . 2018 Aug; 29(10):2085-2091. PMID: 30165371
Background: MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast,...
5.
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al.
Ann Oncol . 2018 Apr; 29(6):1437-1444. PMID: 29617710
Background: The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading...
6.
Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer
Goncalves M, Taylor S, Halpenny D, Schwitzer E, Gandelman S, Jackson J, et al.
Clin Radiol . 2018 Jan; 73(5):505.e1-505.e8. PMID: 29317048
Aim: To assess whether changes in body composition could be assessed serially using conventional thoracic computed tomography (CT) and positron-emission tomography (PET)/CT imaging in patients receiving induction chemotherapy for non-small...
7.
Investigation of patterns of nodal metastases in BRAF mutant lung cancer
McEvoy S, Halpenny D, Viteri-Jusue A, Hayes S, Plodkowski A, Riely G, et al.
Lung Cancer . 2017 Jun; 108:62-65. PMID: 28625649
Axillary lymph nodes (axLN) are a rare site of nodal metastases in patients with lung cancer. BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of...